ストックスクリーナーアプリを入手
1.13
6.60%
0.07
アフターアワーズ：
1.10
-0.03
-2.65%
前日終値:
$1.06
開ける：
$1.09
24時間の取引高:
174.29K
Relative Volume:
1.20
時価総額：
$35.53M
収益：
$90,000
当期純損益:
$-23.47M
株価収益率:
-1.5023
EPS:
-0.7522
ネットキャッシュフロー:
$-22.98M
1週間 パフォーマンス:
+2.73%
1か月 パフォーマンス:
-8.87%
6か月 パフォーマンス:
-9.60%
1年 パフォーマンス:
-22.60%
1日の値動き範囲:
$1.05
$1.15
1週間の範囲:
$0.95
$1.15
52週間の値動き範囲:
$0.7351
$1.74
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
名前
Actinium Pharmaceuticals Inc
セクター
電話
646-767-3870
住所
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.13 | 35.53M | 90,000 | -23.47M | -22.98M | -0.7522 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-07 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-02-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-08-25 | 開始されました | B. Riley Securities | Buy |
| 2020-11-05 | 開始されました | Alliance Global Partners | Buy |
| 2017-12-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | 再開されました | ROTH Capital | Buy |
| 2017-09-14 | 開始されました | Maxim Group | Buy |
| 2016-08-25 | 開始されました | ROTH Capital | Buy |
| 2016-02-29 | 開始されました | H.C. Wainwright | Buy |
| 2015-10-15 | 開始されました | FBR Capital | Outperform |
| 2014-10-01 | 開始されました | MLV & Co | Buy |
| 2014-07-22 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Actinium Pharmaceuticals Inc (ATNM) 最新ニュース
Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive Growth - GlobeNewswire Inc.
Actinium Pharmaceuticals (ATNM) Slips 3.28% to $1.18 as Shares Test Mid-Range SupportFibonacci Fan - siam.in
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Eastern Progress
ATNM: Initiating Coverage – Diversified Nuclear Medicine Portfolio - finance.yahoo.com
Actinium CEO to present at H.C. Wainwright Glob... - Pluang
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Actinium Pharmaceuticals (ATNM) grants director new stock awards - Stock Titan
Actinium Pharmaceuticals (ATNM) grants director $1.00 options and RSUs - stocktitan.net
Actinium (ATNM) Update: Slides 1.79% to $1.10 in Latest Trading; Next Test: Traders Can Monitor the $1.04-$1.16 Range in the Latest SessionBreakout Confirmation - vinanet.vn
Actinium (ATNM) Chart: Ends Up by 3.24% at $1.11 in Latest Trading; Level Watch: the Supplied Trading Band Runs From $1.05 to $1.17Up Down Ratio - vinanet.vn
KPTI Stock Price and Chart — NASDAQ:KPTI - TradingView
ETFs Investing in Actinium Pharmaceuticals, Inc. Stocks - TradingView
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS) - The Globe and Mail
Form 8K Actinium Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property And Manufacturing Advances And Provides NYSE American Listing Update - TradingView
Form 8K Actinium Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com India
Form 8K Actinium Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Canada
Actinium Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update - PR Newswire
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update - finance.yahoo.com
Actinium Pharmaceuticals (ATNM) Slips 3.4% to $0.77 as Key Support at $0.73 Comes into FocusRelative Volume - vinanet.vn
Actinium Pharmaceuticals (ATNM) Institutional Ownership 2026 - MarketBeat
Actinium Pharmaceuticals (ATNM) Falls 7.5% to $0.75 as Selling Pressure IntensifiesGrowth ETF - dars.gov.et
Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. (ATNM) InvestorsLead Plaintiff Deadline on May 27, 2025 - The National Law Review
Actinium Pharmaceuticals, Inc. (Delaware) Revenue Breakdown – AMEX:ATNM - TradingView
Actinium Pharmaceuticals (ATNM) Hovers Near Support With Modest DeclineBullish Pattern Stocks - vinanet.vn
Class Action Lawsuit Filed: Actinium Pharmaceuticals, Inc. (ATNM)Join by May 27, 2025Contact Levi & Korsinsky - The National Law Review
Actinium Pharmaceuticals Inc (ATNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Did You Lose Money on Actinium Pharmaceuticals, Inc. (ATNM)? Levi - The National Law Review
ATNM|Actinium Pharmaceuticals Inc|Price:0.860|Chg%:-0.024 - TradingKey
TradingKey - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Actinium Pharmaceuticals (ATNM) Q3 2025 earnings summary - Quartr
Actinium Pharmaceuticals (ATNM) Life Sciences Investor Forum Summary - Quartr
Actinium Pharmaceuticals (ATNM) Dips 2.9% as Biotech Stock Nears Support ZoneVWAP Breakout - dars.gov.et
Actinium Pharmaceuticals (ATNM) Dips 2.9% as Biotech Stock Nears Support ZoneSchiff Line - vinanet.vn
Actinium Pharmaceuticals (ATNM) Gains 2.77% as Stock Tests Key Resistance Near $0.97Volume Rate Change - vinanet.vn
Actinium Pharmaceuticals (ATNM) Investor presentation Summary - Quartr
Actinium Pharmaceuticals (ATNM) Proxy Filing Summary - Quartr
Actinium Pharmaceuticals (ATNM) Q3 2025 earnings summary - Quartr
Actinium Pharmaceuticals (ATNM) Q4 2025 earnings summary - Quartr
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models - AOL.com
Actinium Company Profile & Introduction - Moomoo
ATNMActinium Pharmaceuticals Inc Earnings - Finviz
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - The National Law Review
ATNMActinium Pharmaceuticals Inc Latest SEC Filings - Finviz
Actinium Pharmaceuticals (ATNM) Stages Recovery Attempt Near Critical Support LevelLong Short Pair - dars.gov.et
ATNM Stockholders Have Opportunity to Lead Actinium Pharmaceutica - The National Law Review
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceut - The National Law Review
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Urged to Joi - The National Law Review
Actinium Pharmaceuticals Inc (ATNM) 財務データ
収益
当期純利益
現金流量
EPS
4.22%
大文字化:
|
ボリューム (24 時間):